semaglutide nash Efficacy and safety of subcutaneous once-daily versus placebo in patients with nonalcoholic steatohepatitis Semaglutide Resolves in Big Placebo-Controlled Trial Semaglutide Has Beneficial Effects on

Global market context

Make sure to yap with your healthcare sidekick to fine-tune your plan and keep your energy levels up

Lilly's retatrutide phase 3 results: 28.3% body weight loss on highest dose May 2026 Eli Lilly's phase 3 results for retatrutide show striking efficacy in obesity treatment: 28.3% body weight loss on the highest dose over 80 weeks approximately 70 lbs on average 45% of participants lost 30% or more of their body weight 65% on the top dose were no longer clinically obese Even the lowest 4mg dose delivered 19% weight loss with fewer dropouts than placebo Retatrutide is a triple-agonist targeting GIP, GLP-1, and glucagon receptors versus one receptor for semaglutide and two for tirzepatide (Mounjaro/Zepbound)

The study would not have been possible without the use of artificial intelligence to weed through dozens of proteins in a class called prohormones

Congress, Senate Resolution 215, "Veterans Affairs Research Week," 119th Congress (2025)